Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 18:19:42 24/07/2024 BST 5-day change 1st Jan Change
6.275 USD -0.40% Intraday chart for Vanda Pharmaceuticals Inc. +0.80% +48.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cantor Fitzgerald Initiates Vanda Pharmaceuticals at Overweight With $11 Price Target MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz MT
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index CI
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index CI
The same old winners Our Logo
Future Pak withdraws offer to buy Vanda Pharmaceuticals RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others. CI
Vanda rejects Future Pak and Cycle Pharma's takeover offers RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc.. CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Softer Thursday Afternoon MT
Sector Update: Health Care MT
Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise MT
Future Pak raises cash portion of buyout offer for Vanda RE
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Sector Update: Health Care MT
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma MT
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million MT
Top Premarket Gainers MT
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. for approximately $490 million. CI
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US MT
Global markets live: UBS, Tesla, Nvidia, Apple, Micron... Our Logo
Vanda Pharmaceuticals rejects Future Pak's revised takeover offer RE
Vanda Pharmaceuticals rejects Future Pak's deal RE
Chart Vanda Pharmaceuticals Inc.
More charts
Logo Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Employees
203
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.300USD
Average target price
8.105USD
Spread / Average Target
+28.65%
Consensus